HC Wainwright reiterated their buy rating on shares of Foghorn Therapeutics (NASDAQ:FHTX – Free Report) in a report published on Monday morning, Benzinga reports. HC Wainwright currently has a $20.00 target price on the stock.
Separately, Wedbush restated an outperform rating and set a $13.00 price objective on shares of Foghorn Therapeutics in a research report on Thursday, August 8th.
Check Out Our Latest Stock Analysis on FHTX
Foghorn Therapeutics Trading Down 5.2 %
Foghorn Therapeutics (NASDAQ:FHTX – Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.45) EPS for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.15. The firm had revenue of $6.89 million for the quarter, compared to analyst estimates of $6.60 million. On average, sell-side analysts predict that Foghorn Therapeutics will post -2.2 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Foghorn Therapeutics
A number of hedge funds have recently made changes to their positions in the stock. Raymond James & Associates increased its holdings in Foghorn Therapeutics by 7.8% in the first quarter. Raymond James & Associates now owns 2,230,456 shares of the company’s stock worth $14,966,000 after purchasing an additional 162,069 shares in the last quarter. Jacobs Levy Equity Management Inc. increased its holdings in Foghorn Therapeutics by 101.1% in the first quarter. Jacobs Levy Equity Management Inc. now owns 216,270 shares of the company’s stock worth $1,451,000 after purchasing an additional 108,700 shares in the last quarter. Vanguard Group Inc. increased its holdings in Foghorn Therapeutics by 7.5% in the first quarter. Vanguard Group Inc. now owns 1,102,493 shares of the company’s stock worth $7,398,000 after purchasing an additional 77,380 shares in the last quarter. Panagora Asset Management Inc. increased its holdings in Foghorn Therapeutics by 180.6% in the fourth quarter. Panagora Asset Management Inc. now owns 97,017 shares of the company’s stock worth $626,000 after purchasing an additional 62,441 shares in the last quarter. Finally, Birchview Capital LP increased its holdings in Foghorn Therapeutics by 21.2% in the fourth quarter. Birchview Capital LP now owns 320,930 shares of the company’s stock worth $2,070,000 after purchasing an additional 56,087 shares in the last quarter. 61.55% of the stock is currently owned by institutional investors.
About Foghorn Therapeutics
Foghorn Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.
Featured Stories
- Five stocks we like better than Foghorn Therapeutics
- 3 REITs to Buy and Hold for the Long Term
- Brinker International’s Price Dip is an Appetizing Entry Point
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- 3 Stocks That Could Beat the September Blues
- Quiet Period Expirations Explained
- Canopy Growth Stock: Can It Sustain Recent Gains?
Receive News & Ratings for Foghorn Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foghorn Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.